Health Care and Biotech

Alcidion’s IT Targets Hospital Efficiency

Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.

Dec 19 2016

Estia Health Beset By Uncertainty

Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.

Dec 13 2016


Rebound For Sirtex

Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.

Dec 13 2016

Sirtex Reaction Overdone

Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.

Dec 12 2016


Previous Stories

Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes

Dec 05 2011

Weekly update on recommendation, target price, and earnings forecast changes.


The Short Report

Nov 29 2011

FNArena’s weekly update on short positions in the Australian share market.


Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes

Nov 21 2011

Weekly update on recommendation, target price, and earnings forecast changes.


Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes

Nov 14 2011

Weekly update on recommendation, target price, and earnings forecast changes.


Prima Biomed And The Topic Of Cancer

Nov 10 2011

Nomura has initiated coverage on Prima Biomed with a Buy rating, attracted to the group’s potential to develop an immunotherapy-based treatment for ovarian cancer.


Treasure Chest: Impedimed Surprises

Nov 07 2011

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. RBS Morgans sees plenty of upside following a surprise announcement by biotech company Impedimed.


Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes

Nov 07 2011

Weekly update on recommendation, target price, and earnings forecast changes.


Mesoblast: Undervalued Or Overvalued?

Nov 03 2011

While Bell Potter has long been a fan of Mesoblast’s stem cell technology, Macquarie initiates with an Underperform rating and argues the market has become over-excited.


Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes

Oct 31 2011

Weekly update on recommendation, target price, and earnings forecast changes.


ResMed Has Become A Post FY12 Story

Oct 26 2011

ResMed’s quarterly report disappointed many and broker responses have been mixed.



Analyse The Market From A Different Angle